| COMPANY |
Hims & Hers Health, Inc. |
| COURT |
United States District Court for the Northern District of California |
| CASE NUMBER |
25-cv-05315 |
| JUDGE |
The Honorable James Donato |
| CLASS PERIOD |
April 29, 2025, through June 23, 2025 |
| SECURITY TYPE |
Securities |
Case Background:
This is a federal securities fraud class action lawsiot on behalf of those who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims”) (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Hims was engaged in deceptive promotion and selling of knockoff versions of Wegovy, an obesity drug by Novo Nordisk; (2) because of this, there was a substantial risk that Hims’ collaboration with Novo Nordisk to sell a bundled offering of Wegovy would be terminated; and (3) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
Motions to Appoint Lead Plaintiff and Lead Counsel were filed on August 25, 2025. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.